Cold tumors? Understanding STK11 and KEAP1 in NSCLC

Podcast | English | 2025 | 53 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez sits down with Dr. Biagio Ricciuti and Dr. Giannis Mountzios to discuss resistance mechanisms for immune checkpoint inhibitors and more about our understanding of STK11 and KEAP1 co-mutations in conjunction with KRAS mutations as independent predictive factors, as well as emerging therapeutics in this space.

Podcast Host:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Giannis Mountzios, MD, Director of the Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece
Biagio Ricciuti, MD, PhD, Thoracic Medical Oncologist and Data Scientist, Dana-Farber Cancer Institute, Faculty, Harvard Medical School, Boston, MA, USA